NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer

Core Insights - NodThera has appointed Dr. Jyothis George as Chief Medical Officer, effective immediately, to lead the clinical advancement of its NLRP3 inflammasome inhibitor portfolio [1][4][5] Company Overview - NodThera is a clinical-stage biotech focused on developing brain-penetrant NLRP3 inflammasome inhibitors for chronic inflammatory diseases, with two lead clinical candidates showing potentially best-in-class profiles [6] - The company is backed by prominent investors including 5AM Ventures, Blue Owl Capital, Epidarex Capital, F-Prime Capital, Novo Holdings, Sanofi Ventures, and Sofinnova Partners [6] Leadership Experience - Dr. Jyothis George brings extensive experience in cardiometabolic drug development, having previously served as Global Medical Vice President at Amgen, where he led strategic planning for obesity treatments [2][3] - His past roles include Corporate Vice President at Novo Nordisk, where he oversaw key clinical trials for drugs like semaglutide, and Global Head of Clinical Development at Boehringer Ingelheim, where he managed pivotal programs for empagliflozin and linagliptin [3] Strategic Vision - The appointment of Dr. George is expected to enhance NodThera's clinical development efforts, leveraging his expertise in regulatory success and landmark trials to advance the company's innovative therapies [4][5] - Dr. George expressed enthusiasm about transforming treatments for diseases linked to chronic low-grade inflammation, aiming to restore metabolic balance for patients [4]